CClinicalTrials.gg
RecruitingNCT07611474Updated May 28, 2026

To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial

An interventional study of Uterine stent group and Uterine ring + balloon + sodium hyaluronate gel in Intrauterine Adhesion and Intrauterine Adhesions, sponsored by The Third Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by The Third Xiangya Hospital of Central South University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

To evaluate the effect of uterine stents in preventing intrauterine adhesions after intrauterine operation and whether they meet the safety requirements for clinical use. The trial adopted a prospective, multicenter, randomized controlled, non-inferiority clinical trial design. The target population of the trial was 200 women aged 20-40 years with intrauterine adhesions and surgical indications (referring to those with fertility requirements or menstrual blood drainage obstruction), who were randomly divided into an experimental group and a control group, with 100 cases in each group. The experimental group was the group with intrauterine stents placed in the uterine cavity after hysteroscopic intrauterine adhesion separation surgery, and the control group was the group with intrauterine rings + balloons + sodium hyaluronate gel placed in the uterine cavity. After 3 courses of artificial cycles, the patients were hospitalized for hysteroscopy review.

02

Conditions studied

  • Intrauterine Adhesion
  • Intrauterine Adhesions

Browse trials for

03

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patients clinically diagnosed with intrauterine adhesions and with surgical indications (referring to those with fertility requirements or obstructed menstrual blood drainage) ② Women aged 20-40 years old; ③ Subjects voluntarily participated in the trial and signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • ① Patients with obviously abnormal uterine cavity shape after surgery; those who could not clearly separate the normal uterine cavity anatomical morphology (i.e. bilateral or unilateral fallopian tube openings were not visible); those with reproductive organ malformations and uterine cavities that were too large or too small; those with recent uterine perforation; those with cervical insufficiency.

    • Those with a history of intrauterine adhesions and treatment;

      • Those with endometrial tuberculosis or suspected endometrial tuberculosis;

        • Those with adenomyosis or uterine fibroids>4cm;

          • Those with a history of malignant tumors or suspected malignant tumors;

            • Those with acute and chronic intrauterine infection and genital infection;

              • Those with unexplained vaginal bleeding or suspected uterine malignant lesions;

                • Those with severe anemia and abnormal coagulation function; those with a history of thrombosis; ⑨ Those in the acute stage of various diseases or severe systemic diseases;

                  • Those with severe mental illness and physical weakness who cannot tolerate this operation;

                    ⑪ Those with severe heart, liver, and kidney function diseases;

                    ⑫ Those with contraindications to anesthesia or surgery;

                    ⑬ Those who have participated in clinical trials in the past three months.

                    • Those who are considered unsuitable for inclusion by the researchers.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Uterine stent placement in the uterine cavity after hysteroscopic intrauterine adhesion separation surgery

    Device: Uterine stent group

  • Experimental
    Control group

    Uterine cavity insertion ring + balloon + sodium hyaluronate gel

    Device: Uterine ring + balloon + sodium hyaluronate gel

Interventions

  • DeviceUterine stent group

    After TCRA, uterine stents of different specifications were placed in the uterine cavity according to the different uterine cavity morphologies of the subjects, and the hysteroscope was inserted again to adjust the position of the uterine stent.

  • DeviceUterine ring + balloon + sodium hyaluronate gel

    The subjects were hospitalized for TCRA surgery. After the surgery, different types of uterine rings were selected and inserted into the uterine cavity according to the morphology of the subjects' uterine cavity. At the same time, a No. 12 Foley catheter was left in the uterine cavity, and 2.5 ml of normal saline was injected into the catheter balloon. 2 ml of hyaluronic acid gel was injected into the uterine cavity on one side of the catheter. The doctor removed the Foley catheter on the first day after the surgery.

05

What researchers measure

Primary outcomes

  1. Intrauterine adhesion rate

    Refer to the 2017 American Fertility Association IUA guidelines AFS score. AFS score: The case with adhesion whose total AFS score decreased by ≥ 4 points was considered effective. The effective rate was calculated using the following formula: number of cases with total AFS score decreased by ≥ 4 points/total number of cases × 100%.

    Time frame: At 12 months after the index hysterectomy

06

Study locations

1 of 1 sites recruiting
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
    Recruiting
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 28, 2020

Documents are hosted by the registry — open the source record to download them.

08

Registry details

Key details

Study ID
NCT07611474
Lead sponsor
The Third Xiangya Hospital of Central South University
Collaborators
Hunan Haokang Medical Technology Co., Ltd., Beijing Tiantan Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Responsible party
Xu dabao (MD, The Third Xiangya Hospital of Central South University) — Principal investigator
First posted
May 28, 2026
Start date
Jan 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
May 28, 2026

Study contacts

Dabao MD
Contact
forxudabao@126.com
13017386201

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion